药格局 YaoGeJuCDE public lists · weekly counts
National Drug-Review Weekly
2023/07/18 – 2023/07/24
- New acceptances this week
- 265
- Drugs with new generic filings (by drug name, de-duplicated)
- 42
- Accepted this week, now under review
- 1
DefinitionAcceptance numbers accepted this week that still appear on CDE's under-review list at the data cutoff; counted by acceptance date from the daily full pull of that list, independent of snapshot history.
Drug and company names link to detail pages; sign in to view them.
New acceptances this week
By application type and drug type
265filings, 54 of them generic
By application type
| Application type | Filings |
|---|---|
| Supplement | 123 |
| Generic | 54 |
| New drug | 51 |
| Import | 22 |
| Unspecified | 11 |
| Import re-registration | 4 |
By drug type
| Drug type | Filings |
|---|---|
| Chemical drug | 166 |
| 治疗用生物制品 | 48 |
| TCM | 47 |
| 预防用生物制品 | 3 |
| Biologic | 1 |
DefinitionAcceptance numbers whose acceptance date falls in this week; application type and drug type are the CDE list's own text, with empty values shown as “Unspecified”.
Most new generic filings, by drug
42 drugs with new generic filings; top 10 listed
| # | Drug | New generic filings | Filing companies | Under review, all years |
|---|---|---|---|---|
| 1 | 注射用头孢他啶阿维巴坦钠 | 2 | 2 | 12 |
| 2 | 硫酸镁钠钾口服用浓溶液 | 2 | 2 | 8 |
| 3 | 二十碳五烯酸乙酯软胶囊 | 2 | 1 | 25 |
| 4 | 吡拉西坦注射液 | 2 | 1 | 9 |
| 5 | 吲哚布芬片 | 2 | 1 | 7 |
| 6 | 富马酸伏诺拉生片 | 2 | 1 | 58 |
| 7 | 普伐他汀钠片 | 2 | 1 | 2 |
| 8 | 注射用头孢唑肟钠 | 2 | 1 | 4 |
| 9 | 盐酸达泊西汀片 | 2 | 1 | 20 |
| 10 | 米诺地尔搽剂 | 2 | 1 | 49 |
DefinitionThis week's acceptance numbers with application type “Generic”, grouped by identical drug name; filing companies are de-duplicated by first applicant; under review, all years = acceptance numbers for that name, from any year, still on the CDE under-review list. Top 10 by filings, then companies.
Most new acceptances, by company
170 companies with new acceptances; top 10 listed
| # | Company (first applicant) | Filings | Drugs | Generic |
|---|---|---|---|---|
| 1 | 四川核力欣健药业有限公司 | 13 | 13 | 0 |
| 2 | 成都第一制药有限公司 | 7 | 3 | 1 |
| 3 | 江右制药（常德）有限公司 | 6 | 5 | 0 |
| 4 | Bristol-Myers Squibb Company | 6 | 2 | 0 |
| 5 | Takeda Development Center Americas Inc. | 5 | 2 | 0 |
| 6 | 海南通用三洋药业有限公司 | 5 | 1 | 0 |
| 7 | 上海信谊万象药业股份有限公司 | 4 | 3 | 0 |
| 8 | 广西修正制药有限公司 | 4 | 3 | 0 |
| 9 | AstraZeneca AB | 3 | 3 | 0 |
| 10 | LGC GmbH | 3 | 3 | 0 |
DefinitionThis week's acceptance numbers grouped by first applicant; drugs are de-duplicated by drug name; “Generic” counts filings with application type “Generic”. Top 10 by filings.
Under-review list changes
Compared across this platform's snapshots of the under-review list
Data collected since 2026/10/22. There is not enough snapshot history for this week yet; counts of filings entering and leaving review start with the next complete week.
DefinitionEntered review = acceptance numbers seen for the first time in this platform's under-review snapshots this week, excluding the baseline records of the first snapshot day (2026/10/22). Left review = acceptance numbers whose last snapshot sighting falls in this week and that this snapshot no longer lists; the outcome follows NMPA's approval-document delivery notices, and numbers without such a record are marked to be checked. Companies are counted by first applicant.
Class 3 and new-drug acceptances
89 this week
59 more not listed (at most 30 rows).
DefinitionThis week's acceptance numbers with application type “New drug”, or registration applications whose class starts with 1, 2 or 3 (supplements and re-registrations excluded); newest first, at most 30 rows.
Subscribe to the weekly
No account needed.
The email carries the same content as this page, in the language you subscribe in: section counts, top-10 lists and definitions, with a link to the full report. Your address is used only to send the report.